Amarin Corporation Plc (AMRN)
Stock Price:
$6.77 USD
0.29 (4.48%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $6.82 +0.05 (0.74%) Aug 3, 6:42 PM
Key Info
| Market Cap |
2.61B |
| Revenue (ttm) |
511.47M |
| Net Income (ttm) |
-18.77M |
| Shares Out |
385.49M |
| EPS (ttm) |
-0.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$6.77 |
| Previous Close |
$6.48 |
| Change ($) |
0.29 |
| Change (%) |
4.48% |
| Day's Open |
6.48 |
| Day's Range |
6.47 - 6.80 |
| Day's Volume |
6,739,677 |
| 52-Week Range |
3.95 - 26.12 |
More Stats
| Market Cap |
2.61B |
| Enterprise Value |
2.11B |
| Earnings Date (est) |
Aug 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
385.49M |
| Float |
347.03M |
| EPS (basic) |
-0.06 |
| EPS (diluted) |
-0.07 |
| FCF / Share |
0.08 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.15% |
| Payout Ratio |
n/a |
| Shares Short |
32.31M |
| Short Ratio |
5.94 |
| Short % of Float |
n/a |
| Beta |
2.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
86.64 |
| PS Ratio |
5.10 |
| PB Ratio |
4.51 |
| Revenue |
511.47M |
| Operating Income |
-25.57M |
| Net Income |
-18.77M |
| Free Cash Flow |
30.13M |
| Net Cash |
499.79M |
| Net Cash / Share |
1.30 |
| Gross Margin |
65.25% |
| Operating Margin |
-5.00% |
| Profit Margin |
-3.70% |
| FCF Margin |
5.89% |
| ROA |
-2.46% |
| ROE |
-5.17% |
| ROIC |
-16.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
7 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.80*
(148.15% upside)
Low
8.00
Current: $6.77
High
51.00
Target: 16.80
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 430 | 229 | 181 | 130 | 81.76 | 54.20 | 26.35 | - | - | - |
| Revenue Growth | 87.49% | 26.56% | 39.22% | 59.11% | 50.84% | 105.69% | - | - | - | - |
| Gross Profit | 334 | 175 | 136 | 95.72 | 53.88 | 33.72 | 14.44 | - | - | - |
| Operating Income | -24.28 | -108 | -45.56 | -65.63 | -98.22 | -95.96 | -182 | -117 | -44.16 | -45.10 |
| Net Income | -22.65 | -116 | -67.87 | -86.35 | -115 | -56.36 | -166 | -179 | -69.13 | -250 |
| Shares Outstanding | 343 | 297 | 271 | 212 | 181 | 174 | 161 | 144 | 130 | 100 |
| Earnings Per Share | -0.07 | -0.39 | -0.25 | -0.41 | -0.83 | -0.36 | -1.28 | -1.24 | -0.53 | -2.49 |
| Operating Cash Flow | -9.37 | -94.70 | -32.84 | -71.82 | -84.02 | -74.61 | -190 | -122 | -39.44 | -33.87 |
| Capital Expenditures | -2.48 | -0.06 | -0.01 | -0.02 | -0.03 | - | -0.01 | -12.69 | -0.40 | -0.02 |
| Free Cash Flow | -11.84 | -94.76 | -32.85 | -71.84 | -84.05 | -74.61 | -190 | -135 | -39.84 | -33.89 |
| Cash & Equivalents | 648 | 251 | 74.24 | 98.85 | 108 | 120 | 193 | 260 | 117 | 31.44 |
| Total Debt | 59.57 | 80.35 | 123 | 116 | 251 | 234 | 261 | 234 | - | 0.09 |
| Net Cash / Debt | 589 | 170 | -48.42 | -17.60 | -144 | -114 | -68.59 | 26.26 | 117 | 31.35 |
| Assets | 882 | 386 | 162 | 167 | 173 | 171 | 252 | 311 | 126 | 35.37 |
| Liabilities | 274 | 233 | 227 | 176 | 301 | 260 | 286 | 315 | 132 | 238 |
| Book Value | 608 | 152 | -65.10 | -9.06 | -128 | -88.45 | -33.86 | -4.00 | -5.96 | -202 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Amarin Corporation Plc |
| Country |
Ireland |
| Employees |
965 |
| CEO |
John F. Thero |
Stock Information
| Ticker Symbol |
AMRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AMRN |
| IPO Date |
April 1, 1993 |
Description
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.